Profile: Brahms Diagnostica, LLC. develops biomarkers for the diagnosis, treatment, and therapeutic management of life-threatening diseases. Our biomarkers include MR-proANP, MR-proADM, CT-proAVP, and CT-proET-1 & are used to improve clinical care of cardiovascular diseases. Our ANP derived from carboxyl terminal amino acids 99-126, which is developed for natriuresis, diuresis, vasodilation, and cardiovascular homeostasis. Our adrenomedullin ADM is a multifunctional peptide synthesized by a variety of tissues including heart and kidney, and it regulates cardiopulmonary function & vascular tone. Our copeptin is a 39-amino acid glycopeptide comprises of C-terminal part of the AVP precursor CT-proAVP. These are used to provide sensitive surrogate markers for AVP releases. Our endothelin is a potent vasoconstrictor, which is implicated in various physiological & pathological processes, including the vascular changes associated with pulmonary hypertension, and sepsis.